We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.68B
AUM Growth
-$109M
Cap. Flow
-$70.1M
Cap. Flow %
-4.17%
Top 10 Hldgs %
48.34%
Holding
155
New
26
Increased
23
Reduced
13
Closed
37

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$26.4M
2
VTYX
Ventyx Biosciences
VTYX
+$20.8M
3
CBIO
Crescent Biopharma
CBIO
+$19.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$18.3M
5
VRDN icon
Viridian Therapeutics
VRDN
+$16.2M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$30.4M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.4M
3
ONC
BeOne Medicines Ltd
ONC
+$23.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.97%
2 Consumer Discretionary 5.18%
3 Financials 0.37%
4 Real Estate 0.31%
5 Technology 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
1
Lexicon Pharmaceuticals
LXRX
$1.03B
$218M 12.96%
89,778,234
– –
ONC
2
BeOne Medicines Ltd
ONC
$34B
$108M 6.42%
501,335
-98,665
-16% -$23.7M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$80.2M 4.77%
1,216,312
+316,312
+35% +$18.3M
SRRK icon
4
Scholar Rock
SRRK
$5.88B
$72.2M 4.29%
9,027,950
+47,680
+0.5% +$484K
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$68.3M 4.06%
1,813,949
-336,051
-16% -$12.4M
WW
6
DELISTED
WW International
WW
$61.1M 3.63%
14,818,300
– –
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$57.2M 3.4%
1,537,709
-295,049
-16% -$13.3M
KYMR icon
8
Kymera Therapeutics
KYMR
$8.66B
$53.5M 3.18%
1,805,346
-194,654
-10% -$6.28M
CYTK icon
9
Cytokinetics
CYTK
$10.6B
$48.1M 2.86%
1,367,023
+367,023
+37% +$15M
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$46.8M 2.78%
1,817,349
-182,651
-9% -$5.34M
CERE
11
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$46.7M 2.77%
1,914,466
+14,466
+0.8% +$425K
RVMD icon
12
Revolution Medicines
RVMD
$38.4B
$44.9M 2.67%
2,070,988
+1,070,988
+107% +$26.4M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$39.1M 2.32%
3,526,407
-473,593
-12% -$5.84M
IGMS
14
DELISTED
IGM Biosciences
IGMS
$34.5M 2.05%
2,509,972
+59,972
+2% +$1.24M
KRYS icon
15
Krystal Biotech
KRYS
$10.7B
$33M 1.96%
412,082
+12,082
+3% +$949K
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$31.5M 1.87%
750,000
– –
RLAY icon
17
Relay Therapeutics
RLAY
$4B
$27.6M 1.64%
1,673,743
+219,027
+15% +$3.93M
SE icon
18
Sea Limited
SE
$66.4B
$26.2M 1.56%
302,500
+130,000
+75% +$8.88M
AGEN
19
Agenus
AGEN
$276M
$23.8M 1.41%
796,411
+57,636
+8% +$2.44M
KLRS
20
Kalaris Therapeutics
KLRS
$80.4M
$22M 1.31%
242,486
– –
VIGL
21
DELISTED
Vigil Neuroscience
VIGL
$22M 1.31%
2,243,352
– –
KURA icon
22
Kura Oncology
KURA
$792M
$21M 1.25%
1,718,056
+18,056
+1% +$225K
DNLI icon
23
Denali Therapeutics
DNLI
$3.78B
$18.5M 1.1%
802,899
+2,899
+0.4% +$79.8K
SDGR icon
24
Schrodinger
SDGR
$1.13B
$18.4M 1.1%
700,000
– –
SEER icon
25
Seer Inc
SEER
$114M
$18.3M 1.09%
4,750,000
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2023 Portfolio in Review

As of Q1 2023, Artal Group held 155 positions worth $1.68B, down 6.1% from $1.79B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $70.1M in Q1 2023, closing 37 positions and reducing 13 holdings. Its most notable exit was BELLUS Health Inc., an estimated $30.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Ventyx Biosciences worth $17.9M.

  • Artal Group's largest Q1 2023 buy was Ventyx Biosciences: 535,812 shares worth $17.9M.
  • Artal Group added most to Revolution Medicines in Q1 2023, an estimated $26.4M increase.
  • Artal Group's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $28.4M.
  • Artal Group fully exited BELLUS Health Inc. in Q1 2023, selling an estimated $30.4M.
  • Artal Group's ten largest holdings make up 48% of its $1.68B portfolio in Q1 2023.
  • Artal Group opened 26 new positions and closed 37 in Q1 2023.
  • Artal Group's portfolio value fell 6.1% quarter-over-quarter to $1.68B.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.